Second‐line chemotherapy for recurrent carcinoma of the ovary

Abstract

Despite relatively high response rates to chemotherapy for ovarian carcinoma, most patients eventually will have progressive disease that will require additional therapy. Most efforts to study such second‐line or “salvage” chemotherapy have been single‐arm trials of small numbers of patients, which report widely variable response rates, relatively short response durations, and short survival times. Only recently have certain critical patient characteristics been recognized as important in determining appropriate therapy as follows: (1) the extent and volume of disease at recurrence and (2) the type and duration of response to prior chemotherapy. Patients with small‐volume disease confined to the peritoneal cavity have a far better chance of achieving a response to second‐line chemotherapy with subsequent prolonged survival than do those with bulky disease or disease outside the abdomen. Perhaps even more critical is the distinction between those patients whose neoplasm is still “clinically sensitive” to the platinum‐containing compounds (initial response to platinum‐based therapy and relapse more than 6 months after cessation of treatment) and those with “clinically resistant” disease (progression during or within 6 months of front‐line platinum‐based therapy). Those considered clinically sensitive to platinum‐based therapy should be retreated with a platinum‐containing regimen at the time of recurrence. Those with evidence for resistance should receive alternative treatment with one or more drugs capable of inducing responses in such patients. These drugs currently include: taxol, ifosfamide, and hexamethylmelamine.